Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

Transplantation

Volumn 70, Issue 8, 2000, Pages 1174-1180

  Kletzmayr, Josef ^a   Kreuzwieser, Evelyn ^a   Watkins Riedel, Thomas ^a   Berlakovich, Gabriele ^a   Kovarik, Josef ^a   Klauser, Renate ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0034721845     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200010270-00008     Document Type: Article

References (55)

1. Cytomegalovirus infection and renal transplantation
2. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation
3. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity
4. Cytomegalovirus as a risk factor in renal transplantation
5. Morbid outcome of cytomegalovirus-negative transplant recipients receiving cytomegalovirus-positive kidneys
6. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation
7. Cytomegalovirus infections after kidney transplantation: Identical risk whether donor or recipient is the virus carrier
8. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients
9. Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigen by enzyme-linked immunosorbent assay
10. Evaluation of cytomegalovirus (CMV) antibody screening tests for blood donors
11. Use of isolated nuclei in the indirect fluorescent antibody test for human cytomegalovirus infection: Comparison with microneutralization, anticomplement, and conventional indirect fluorescent-antibody assays
12. Rapid deduction of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen
13. Detection of CMV in clinical specimens by virus isolation and by monoclonal antibody against the early nuclear antigen
14. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes
15. Experience with a new monoclonal antibody against pp65 for early diagnosis of CMV-infection in renal transplantation
16. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
17. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation
18. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant
19. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease
20. New developments in cytomegalovirus prevention and management
21. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant recipients
22. Cytomegalovirus prophylaxis in pediatric renal transplant recipients
23. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients
24. Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients
25. The impact of donor/recipient matching for cytomegalovirus compatibility or identity on the incidence of disease and outcome following renal transplantation
26. The evaluation of candidates for renal transplantation
27. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients
28. Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients
29. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients
30. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
31. A randomized, placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
32. Cytomegalovirus infection and the role of ganciclovir prophylaxis in transplant recipients
33. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalo-virus-hyperimmune globulin and low-dose acyclovir
34. Pharmakologie von Ganciclovir
35. Phase I pharmacokinetics of the acyclovir prodrug, valacyclovir
36. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
37. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients
38. Ganciclovir prophylaxis of cytomegalovirus disease
39. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts
40. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients
41. Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant 'CMV at risk' recipients: A controlled, comparative study of two regimens (750 mg bid and 500 mg bid)
42. A comparative study of 500 mg bid and 250 mg bid of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients
43. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
44. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
45. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients
46. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients
47. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
48. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients
49. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: Is emergence of resistance imminent?
50. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
51. Development of ganciclovir resistance during treatment of primary CMV infection after liver transplantation
52. Failure of ganciclovir treatment associated with selection of a ganciclovir resistant cytomegalovirus strain in a lung transplant recipient
53. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood
54. The clinical significance of ganciclovir resistance in a renal transplant patient